Contents

List of abbreviations

Chapter 1 General introduction and outline of the thesis


Chapter 3 Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer (BJU Int 2012; 109: 183-8)

Chapter 4 Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry (J Urol 2012; 187: 1601-6)

Chapter 5 Treatment with luteinizing hormone-releasing hormone antagonists: is serum testosterone reduction the only mechanism? (J Drug Res Dev 2016; 2: doi http://dx.doi.org/10.16966/2470-1009.117)

Chapter 6 Relationship between body mass index and serum testosterone concentration in patients receiving luteinising hormone-releasing hormone agonist therapy for prostate cancer (Urology 2013; 81: 1005-9)

Chapter 7 Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer (World J Urol 2012; 31: 261-6)

Chapter 8 Risk of disease flare with LHRH-agonist therapy in men with prostate cancer: myth or fact? (Urol Oncol 2015; 33: 7-15)

Chapter 9 Summarizing discussion and concluding remarks Dutch summary – Nederlandse samenvatting Acknowledgements – Dankwoord Curriculum Vitae List of publications